INBX (Inhibrx Biosciences) Gross-Profit-to-Asset % : 0.20% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Inhibrx Biosciences's annualized Gross Profit for the quarter that ended in Dec. 2024 was $0.40 Mil. Inhibrx Biosciences's average Total Assets over the quarter that ended in Dec. 2024 was $201.66 Mil. Therefore, Inhibrx Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.20%.

Inhibrx Biosciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Inhibrx Biosciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Gross-Profit-to-Asset % Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

7.82

1.11

0.08

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				2.12	-	0.28	-	0.20

Competitive Comparison of Inhibrx Biosciences's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Inhibrx Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx Biosciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Inhibrx Biosciences Gross-Profit-to-Asset % Calculation

Inhibrx Biosciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0.2	/	( (307.893	+	180.767)	/ 2 )
	=	0.2	/	244.33
	=	0.08 %

Inhibrx Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0.4	/	( (222.562	+	180.767)	/ 2 )
	=	0.4	/	201.6645
	=	0.20 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Inhibrx Biosciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.